Cancer
-
Missed NHS England cancer‑treatment target threatens bladder‑cancer surgery waiting times
Failure to meet the 62‑day target could leave thousands of bladder‑cancer patients waiting longer for surgery, raising survival risks.
-
AstraZeneca’s Imfinzi Wins FDA Approval for Bladder Cancer Patients
The new perioperative regimen cuts death risk by 42% in cisplatin-ineligible patients, marking a major expansion for AstraZeneca’s oncology portfolio.
-
FDA RMAT and Fast Track Designations Set New Evidence Bar for Cell Therapies
Discover the preliminary clinical evidence thresholds cell therapies must achieve to secure simultaneous FDA RMAT and Fast Track designations.
-
How mRNA Technology Is Transforming the Future of Personalized Cancer Vaccines
Following successful Phase 3 trial results, mRNA platforms are emerging as a versatile, rapid tool for training the immune system to target…
-
NHS rolls out first targeted anal cancer drug, extending survival to nearly three years
Retifanlimab plus chemotherapy adds 10 months of life for 250 patients annually in England, available immediately.
-
How the OncoMate MSI Dx Test Guides Pembrolizumab Therapy
Discover how the OncoMate MSI Dx test uses PCR technology to identify MSI-H solid tumors and match patients with pembrolizumab immunotherapy.
-
Financial and Systemic Barriers Impede Early Bladder Cancer Care for Younger Veterans
A new national survey reveals that 63% of military service members and veterans with non-muscle invasive bladder cancer face severe systemic care…
-
Experimental Drug Combo Doubles One-Year Survival Rates in Pancreatic Cancer Trial
A new study shows that adding an experimental drug to standard chemotherapy significantly improves survival outcomes for patients with metastatic pancreatic cancer.
-
UCSF Scientists Eliminate Deadly Brain Tumors in Mice with B-SYNC Therapy
Engineered B-SYNC CAR-T cells successfully wiped out diffuse midline glioma in mice, paving the way for human clinical trials as early as…
-
Medicare Denies $949 Multi-Cancer Blood Test, Leaving Seniors With Full Bill Until 2029
Despite FDA advisory support, CMS excludes Galleri from coverage, forcing patients to pay out-of-pocket while awaiting a 2029 policy shift.
-
Understanding Metastatic Prostate Cancer Prognosis and Modern Treatment Pathways
As Joe Biden scales back public appearances due to metastatic prostate cancer, we examine the clinical realities of high-risk disease and current…
-
Star Health’s ₹780 Crore Cancer Payouts Signal Rising Claims Burden for Policyholders
Insurer settles 85,900 cancer claims in H1 FY27, with women and the 51-60 age group driving a 17% surge in payouts.
-
Overcoming Immunotherapy Resistance Takes Center Stage at SITC 2026
Researchers at the SITC annual meeting tackle major cancer immunotherapy challenges, from metabolic resistance mechanisms to novel combination trials.
-
How Amivantamab’s Dual EGFR-MET Blockade Overcomes Resistance in Head and Neck Cancer
The first new drug in a decade for advanced HNSCC uses a bispecific antibody to hit two escape pathways at once, doubling…
-
Researchers find biological clues to why colorectal cancer strikes young adults
A new cell-by-cell tumor atlas sheds light on the aggressive nature of colorectal cancer in younger populations as screening rates expand.
-
Personal Factors Driving Cancer Biomarker Decisions and Patient Outcomes
Gosselaar’s campaign highlights how personal health history and financial access shape biomarker testing choices and treatment precision.
-
Dendritic Cell Cancer Vaccines: One FDA Approval, Most Others Still in Trials
Only sipuleucel-T is approved for advanced prostate cancer; private clinics like Immunocine in Mexico sell personalized dendritic cell therapies still in clinical…
-
CAR-T Cell Therapy Explained: How It Works, Approved Blood Cancers, and Key Risks
An oncologist’s viral reel calls it revolutionary; here is the plain guide to the treatment, its FDA-approved uses, response data, and serious…
-
Nicole Eggert’s Cancer Bills and a Trial That Cut Financial Toxicity for Patients
Despite insurance, out-of-pocket costs and lost wages create fiscal survival challenges for patients, as seen in Nicole Eggert’s battle.
-
Legal Battles Over Cancer Funding Delay Life-Saving Care for Patients
Court rulings on liability and funding disputes force patients to wait years for verdicts, while Medicare recovery rules threaten to consume settlement…
-
Why Microsatellite Instability Status Dictates Rectal Cancer Treatment Choices
MSI-H status identifies rectal cancer patients who may avoid surgery via dostarlimab, a new FDA-approved immunotherapy targeting defective DNA repair.
-
Enoki Mushrooms and Cancer: What Mouse Studies and Nagano Data Really Show
Animal trials used purified extracts to boost immunity in mice, while a 1989 Japanese study linked lower cancer rates in farmers to…
-
What Clinical Trials Really Show About Tigilanol Tiglate from the Blushwood Berry
A viral social media post revived interest in the rainforest drug, but current human trials reveal targeted local results rather than a…
-
Understanding CIPI: Envita Medical Centers’ In-Tumor Injection Treatment
A neutral explainer detailing what Chemo Immuno Precision Injections are, how the procedure works at Envita Medical Centers, and its evidence status.
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
Study Links High Sugar Intake to 28% Higher Breast Cancer Risk in Korean Women
-
Dexcom CONNECT Study Shows CGM Lowers A1C by 1.6% in Non-Insulin Type 2 Diabetes
-
How Satri-Cel Became the World’s First Approved Solid Tumor CAR-T
-
Missed NHS England cancer‑treatment target threatens bladder‑cancer surgery waiting times
-
AstraZeneca’s Imfinzi Wins FDA Approval for Bladder Cancer Patients
-
How Kazia’s Nuclear PD-L1 Degrader Aims to Overcome Cancer Resistance
-
FDA RMAT and Fast Track Designations Set New Evidence Bar for Cell Therapies
-
How mRNA Technology Is Transforming the Future of Personalized Cancer Vaccines
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
-
How the 2027 401(k) Limit Increase to $25,500 Changes Retirement Planning
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992